Parkinsons Disease Therapeutics Companies

AbbVie Launched their Duopa Intralipid (levodopa/carbidopa intestinal gel) for patients with advanced Parkinson's disease experiencing "off" periods when medication effectiveness diminishes. Collaborating with research institutions on exploring alpha-synuclein targeting therapies, a potential approach to slow disease progression.

Roche Received FDA approval for YELMIO (foneprezil) for the treatment of levodopa-induced dyskinesia, a common side effect of Parkinson's disease medication. Focusing on developing gene therapy candidates for Parkinson's disease, aiming to address the underlying cause of the disease.

Biogen Conducted a positive Phase 2 trial of BIIB0501, a potential neuroprotective therapy for Parkinson's disease, showing promise in slowing disease progression. Partnering with patient advocacy groups to raise awareness about Parkinson's disease and support research efforts.

Novartis Received FDA approval for Kynmobi (apomorphine hydrochloride injection) for continuous subcutaneous infusion to treat "off" periods in Parkinson's disease. Investing in research on stem cell therapies for Parkinson's disease, exploring potential for regenerating dopamine-producing neurons.

Denali Therapeutics Presented encouraging data at the Alzheimer's Association International Conference on their investigational Tau aggregation inhibitor for Parkinson's disease. Focused on developing therapies targeting different aspects of the disease beyond just dopamine replacement.

• Salix Pharmaceuticals


• GlaxoSmithKline Plc


• Impax Laboratories LLC


• Teva Pharmaceutical Industries Ltd


• Novartis AG


• Orion Corporation


• Mylan N.V.


• Par Pharmaceutical


• Cipla Inc.


• Daiichi Sankyo